Qiagen N.V.

  • WKN: A2DKCH
  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 24.12.2019 | 19:26

QIAGEN N.V.: QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation

QIAGEN N.V. / Key word(s): Strategic Company Decision/Takeover
QIAGEN N.V.: QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation

24-Dec-2019 / 19:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation

QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation

Venlo, The Netherlands, December 24, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces that it has concluded the previously announced review of potential strategic alternatives, and has determined the execution of its current stand-alone business plan represents the best opportunity to drive future value creation.

The Management Board and Supervisory Board of QIAGEN, in accordance with their fiduciary duties and in consultation with their financial and legal advisors, held discussions with interested parties to explore potential strategic alternatives that could provide greater value creation opportunities than QIAGEN's already strong stand-alone growth prospects. This process was announced in mid-November after QIAGEN received several conditional, non-binding indications of interest for a full acquisition.

On December 24, 2019, the Management Board and Supervisory Board determined that the alternatives to the stand-alone business plan prospects were not compelling and has terminated all discussions so that the full management focus can be on executing the stand-alone plan

QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
ISIN: NL0012169213
Frankfurt Stock Exchange, regulated market (Prime Standard)

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711 and +1 240 686 2222
john.gilardi@qiagen.com

Phoebe Loh
Associate Director Investor Relations
+49 2103 29 11457
phoebe.loh@qiagen.com

Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49 2103 29 11826 and +1 240 686 7425
thomas.theuringer@qiagen.com

Robert Reitze
Senior Manager Public Relations
+49 2103 29 11676
robert.reitze@qiagen.com


24-Dec-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

25. September 2020